Does Itraconazole Cause Heart Failure?
Itraconazole, an antifungal medication, carries a known risk of congestive heart failure (CHF), particularly in patients with pre-existing heart conditions. The FDA added a black box warning in 2001 after post-marketing reports linked it to CHF exacerbation or onset. Cases often involve negative inotropic effects, where the drug impairs heart muscle contraction, leading to fluid buildup and reduced cardiac output.[1][2]
How Common Is This Risk?
Negative inotropic effects occur in about 1-5% of patients, based on clinical data and case series. A 2011 review in Drug Safety analyzed 50+ reports, finding most cases resolved after discontinuation, but some progressed to hospitalization or death, especially with prolonged use (>1 month).[3] Risk is dose-dependent; higher doses (e.g., 400 mg/day) increase incidence compared to lower ones.[2]
Who Is Most at Risk?
Patients with underlying heart disease face the highest risk:
- History of CHF, ventricular dysfunction, or recent myocardial infarction.
- Those on concurrent negative inotropes (e.g., calcium channel blockers like verapamil).
- Elderly patients or those with risk factors like hypertension or COPD.
Avoid in active CHF; monitor closely in at-risk groups with echocardiograms if symptoms like dyspnea or edema appear.[1][4]
What Do Studies Show?
- A 2009 Dutch cohort study (n=678) found itraconazole raised CHF risk 2.5-fold vs. fluconazole (OR 2.5, 95% CI 1.1-5.7).[5]
- FDA adverse event database (through 2015) logged 200+ CHF cases, with 10% fatal.[2]
- Mechanistic studies confirm itraconazole inhibits L-type calcium channels in cardiac myocytes, mimicking calcium blocker toxicity.[6]
Alternatives for At-Risk Patients
Switch to safer antifungals like fluconazole or voriconazole, which lack strong CHF warnings. Posaconazole has lower cardiac risk but still requires monitoring. For severe cases, consult infectious disease specialists for non-azole options like amphotericin B.[4][7]
Monitoring and Prevention
Baseline cardiac evaluation before starting; discontinue at first CHF sign. Pulse oximetry and ECG help detect early changes. No routine QT prolongation with itraconazole, unlike some azoles.[1]
Sources
[1]: FDA Label for Sporanox (itraconazole)
[2]: FDA Adverse Event Reporting System (FAERS) summary
[3]: Drug Safety 2011;34(4):255-68
[4]: UpToDate: Itraconazole drug information
[5]: Pharmacotherapy 2009;29(11):1276-83
[6]: Circulation 2000;102(13):1581-7
[7]: IDSA Guidelines for Aspergillosis